Protalix BioTherapeutics, Inc. (PLX) Institutional Ownership

Ownership Summary

Protalix BioTherapeutics, Inc. (NYSE:PLX) currently has 2 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• These investors collectively held 0.0% of the company's total shares outstanding in December 2025, down from 18.0% in September 2025.
• Quarterly data indicates a nan% shift in institutional share volume, and the annual owner count reflects a decrease of 95.74%.
• Among the 2 institutional holders of Protalix BioTherapeutics, 2 added to their stakes while 0 trimmed their positions and 0 held steady.
• The aggregate institutional position in Protalix BioTherapeutics now stands at 17.51K shares as of December 2025, after investors increased their holdings (up by 17.51K shares quarter on quarter which is down 3.42Mn shares year over year).
• As of December 31, 2025, SG Americas Securities, LLC held Protalix BioTherapeutics's largest shareholding position with over 17.16K shares, representing 0.02% of total outstanding shares.
• Among the most significant buyers of Protalix BioTherapeutics during December 2025 were SG Americas Securities, LLC (17.16K), GAMMA Investing LLC (355).
• The top 2 institutional holders of Protalix BioTherapeutics for the quarter ending December 2025 included SG Americas Securities, LLC (17.16K), GAMMA Investing LLC (355).